GSK, ALXN, REGN And LLY, 4 Drugs Stocks Pushing The Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 32 points (-0.2%) at 15,645 as of Thursday, Sept. 19, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,343 issues advancing vs. 1,599 declining with 112 unchanged.

The Drugs industry currently sits up 0.2% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Amgen ( AMGN), down 1.3%, Celgene Corporation ( CELG), down 0.8%, Novartis ( NVS), down 0.7% and Gilead ( GILD), down 0.6%. A company within the industry that increased today was Bristol-Myers Squibb Company ( BMY), up 1.2%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. GlaxoSmithKline ( GSK) is one of the companies pushing the Drugs industry lower today. As of noon trading, GlaxoSmithKline is down $0.81 (-1.6%) to $50.46 on average volume. Thus far, 1.4 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $50.45-$51.18 after having opened the day at $51.15 as compared to the previous trading day's close of $51.27.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $125.3 billion and is part of the health care sector. Shares are up 17.6% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Alexion Pharmaceuticals ( ALXN) is down $2.21 (-1.9%) to $113.72 on average volume. Thus far, 568,458 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $112.57-$116.24 after having opened the day at $116.07 as compared to the previous trading day's close of $115.93.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $22.3 billion and is part of the health care sector. Shares are up 21.9% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $8.67 (-2.8%) to $300.50 on heavy volume. Thus far, 639,556 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 708,800 shares. The stock has ranged in price between $298.11-$310.63 after having opened the day at $309.91 as compared to the previous trading day's close of $309.17.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $28.7 billion and is part of the health care sector. Shares are up 80.7% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Eli Lilly and Company ( LLY) is down $0.44 (-0.8%) to $53.72 on light volume. Thus far, 1.7 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 4.9 million shares. The stock has ranged in price between $53.63-$54.12 after having opened the day at $53.90 as compared to the previous trading day's close of $54.16.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $60.6 billion and is part of the health care sector. Shares are up 9.1% year to date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Eli Lilly and Company a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and increase in stock price during the past year. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Eli Lilly and Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null